公开(公告)号：US20240009215A1

公开(公告)日：2024-01-11

申请号：US18360909

申请日：2023-07-28

Applicant: Novartis AG

Inventor： Michael Cooke ,  Shailaja Kasibhatla ,  Andrew T. Miller ,  Tom Yao-Hsiang Wu

IPC: A61K31/675 ,  A61P35/04 ,  A61K9/00 ,  A61K9/10 ,  A61K9/19 ,  A61K47/02 ,  A61K47/26 ,  C07K16/28

CPC classification number: A61K31/675 ,  A61P35/04 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/19 ,  A61K47/02 ,  A61K47/26 ,  C07K16/2818

Abstract: The invention provided herein includes pharmaceutical compositions comprising a TLR7 agonist having the structure of Formula (A), aluminum-containing particles, and one or more pharmaceutically acceptable excipient. The invention further provides the use of such compositions in the treatment of solid tumors either alone or in combination with one or more additional pharmaceutical compositions.

公开(公告)号：US11752162B2

公开(公告)日：2023-09-12

申请号：US16614280

申请日：2018-05-17

Applicant: Novartis AG

Inventor： Michael Cooke ,  Shailaja Kasibhatla ,  Andrew T. Miller ,  Tom Yao-Hsiang Wu

IPC: A61P35/04 ,  A61K31/675 ,  A61K9/00 ,  A61K9/10 ,  A61K9/19 ,  A61K47/02 ,  A61K47/26 ,  C07K16/28

CPC classification number: A61K31/675 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/19 ,  A61K47/02 ,  A61K47/26 ,  A61P35/04 ,  C07K16/2818

Abstract: The invention provided herein includes pharmaceutical compositions comprising a TLR7 agonist having the structure of Formula (A), aluminum-containing particles, and one or more pharmaceutically acceptable excipient. The invention further provides the use of such compositions in the treatment of solid tumors either alone or in combination with one or more additional pharmaceutical compositions.

公开(公告)号：US20210154214A1

公开(公告)日：2021-05-27

申请号：US16614280

申请日：2018-05-17

Applicant: Novartis AG

Inventor： Michael Cooke ,  Shailaja Kasibhatla ,  Andrew T. Miller ,  Tom Yao-Hsiang Wu

IPC: A61K31/675 ,  A61K9/19 ,  A61K9/00 ,  A61P35/04 ,  C07K16/28 ,  A61K47/02 ,  A61K47/26 ,  A61K9/10

Abstract: The invention provided herein includes pharmaceutical compositions comprising a TLR7 agonist having the structure of Formula (A), aluminum-containing particles, and one or more pharmaceutically acceptable excipient. The invention further provides the use of such compositions in the treatment of solid tumors either alone or in combination with one or more additional pharmaceutical compositions.